Wockhardt gets US FDA nod to market Ceftazidime injections





Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for marketing the injections containing 1 Gm/Vial Ceftazidime, which is used for treating various kinds of infections. Ceftazidime is the generic name for the brand Fortaz, sold in the US by Glaxo Smithkline.

Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for marketing the injections containing 1 Gm/Vial Ceftazidime, which is used for treating various kinds of infections. Ceftazidime is the generic name for the brand Fortaz, sold in the US by Glaxo Smithkline.

Wockhardt Chairman Habil Khorakiwala said, Wockhardt is one of the only three companies to have received this approval. This product required significant R&D activity in both API and injections and is a reflection of the multi-faceted capabilities of Wockhardt to meet the challenges of the US markets.”Wockhardt’s Ceftazidime injections will be launched in the US very shortly.

Ceftazidime is used in treating several kinds of infections and is one of the most potent, powerful and safe antibiotics.The Ceftazidime pentahydrate API is manufactured in the FDA approved API facility at Ankleshwar, Gujarat and the injections are manufactured at the US FDA certified formulation plant at Waluj, Maharashtra. The API and the product were developed in-house.